Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Seeger

Showing results (251-260 of 266) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastomaShahab Asgharzadeh, Jill A Salo, Lingyun Ji, et al.
Genome Research|August 16, 2020
Somatic structural variation targets neurodevelopmental genes and identifies <i>SHANK2</i> as a tumor suppressor in neuroblastomaGonzalo Lopez, Karina L Conkrite, Miriam Doepner, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and PrognosisAraz Marachelian, Judith G Villablanca, Cathy W Liu, et al.
Oncotarget|February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology groupRisa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.
Cancer Letters|December 20, 2015
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastomaShile Zhang, Jun S Wei, Samuel Q Li, et al.
Pediatric Blood & Cancer|June 30, 2012
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology CommitteeRie Suganuma, Larry L Wang, Hideki Sano, et al.
Oncogene|January 24, 2012
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaE L Carpenter, E A Haglund, E M Mace, et al.
Nature Genetics|May 5, 2009
Common variations in BARD1 influence susceptibility to high-risk neuroblastomaMario Capasso, Marcella Devoto, Cuiping Hou, et al.
Pageof 27

Showing results (251-260 of 266) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastomaShahab Asgharzadeh, Jill A Salo, Lingyun Ji, et al.
Genome Research|August 16, 2020
Somatic structural variation targets neurodevelopmental genes and identifies <i>SHANK2</i> as a tumor suppressor in neuroblastomaGonzalo Lopez, Karina L Conkrite, Miriam Doepner, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and PrognosisAraz Marachelian, Judith G Villablanca, Cathy W Liu, et al.
Oncotarget|February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology groupRisa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.
Cancer Letters|December 20, 2015
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastomaShile Zhang, Jun S Wei, Samuel Q Li, et al.
Pediatric Blood & Cancer|June 30, 2012
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology CommitteeRie Suganuma, Larry L Wang, Hideki Sano, et al.
Oncogene|January 24, 2012
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaE L Carpenter, E A Haglund, E M Mace, et al.
Nature Genetics|May 5, 2009
Common variations in BARD1 influence susceptibility to high-risk neuroblastomaMario Capasso, Marcella Devoto, Cuiping Hou, et al.
Pageof 27